Bristol-Myers Squibb slides as Q1 beat fails to lift unchanged 2026 outlook
BMY•Bristol-Myers Squibb shares fell Friday, May 1, 2026, after the company’s April 30 Q1 2026 update reaffirmed full-year guidance rather than raising it. Investors focused on continued erosion in the legacy portfolio (down 6% year over year) despite a Q1 beat and 12% growth-portfolio growth to $6.2 billion.
1. What’s moving the stock today
Bristol-Myers Squibb (BMY) is trading lower on Friday, May 1, 2026, as the market digests its first-quarter 2026 update released April 30. While the company reported results ahead of expectations, the key headline for many investors was that Bristol-Myers reaffirmed (did not raise) its 2026 revenue outlook of about $46.0 billion to $47.5 billion and non-GAAP EPS guidance of $6.05 to $6.35, even as it said results are trending toward the upper end of the ranges. (bms.com)
